HHCYH-33 is under clinical development by Shanghai Haihe Biopharma and currently in Phase I for Cervical Cancer. According to GlobalData, Phase I drugs for Cervical Cancer have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how HHCYH-33’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

HHCYH-33 overview

HHCYH-33 is under development for the treatment of solid tumor including metastatic esophageal, gastroesophageal junction squamous cell carcinoma, ovarian cancer, prostate cancer, breast cancer, cervical cancer, head and neck squamous cell carcinoma, gastric cancer, fallopian tube cancer, HER-2 negative breast cancer, endometrial cancer and primary peritoneal cancer. It is administered through oral route as a tablet. The drug candidate acts by targeting phosphatidylinositol 3-kinase alpha (PI3K-alpha).

Shanghai Haihe Biopharma overview

Shanghai Haihe Biopharma (Haihe Biopharma), is a manufacturer and distributer of medical products. It produces cancer anti-tumour drugs. Haihe Biopharma is headquartered in Shanghai, China.

For a complete picture of HHCYH-33’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.